Israel - English - Ministry of Health

novo nordisk ltd., israel - insulin aspart - suspension for injection - insulin aspart 100 u/ml - insulin aspart - insulin aspart - novomix® 30 is indicated for treatment of diabetes mellitus in adults, adolescents and children aged 10 years and above. משטר מינון : 7/8/2019posology and method of administrationposologythe potency of insulin analogues, including insulin aspart, is expressed in units, whereas the potency of human insulin is expressed in international units.novomix ®30 dosing is individual and determined in accordance with the needs of the patient. blood glucose monitoring and insulin dose adjustments are recommended to achieve optimal glycaemic control.in patients with type 2 diabetes, novomix® 30 can be given as monotherapy. novomix® 30 can also be given in combination with oral antidiabetic medicinal products and/or glp-1 receptor agonists . for patients with type 2 diabetes, the recommended starting dose of novomix® 30 is 6 units at breakfast and 6 units at dinner (evening meal). novomix® 30 can also be initiated once daily with 12 units at dinner (evening meal). when using novomix® 30 once daily, it is generally recommended to move to twice daily when reaching 30 units by splitting the dose into equal breakfast and dinner doses. if twice daily dosing with novomix ®30 results in recurrent daytime hypoglycaemic episodes, the morning dose can be split into morning and lunchtime doses (thrice daily dosing).the following titration guideline is recommended for dose adjustments:pre-meal blood glucose level novomix® 30 dose adjustment<4.4 mmol/l <80 mg/dl -2 units4.4–6.1 mmol/l 80–110 mg/dl 06.2–7.8 mmol/l 111–140 mg/dl +2 units7.9–10 mmol/l 141–180 mg/dl +4 units>10 mmol/l >180 mg/dl +6 unitsthe lowest of the three previous days’ pre-meal blood glucose levels should be used. the dose should not be increased if hypoglycaemia occurred within these days. dose adjustments can be made once a week until target hba1c is reached. pre-meal blood glucose levels should be used to evaluate the adequacy of the preceding dose.in patients with type 2 diabetes, a dose reduction of 20% is recommended for patients with an hba1c less than 8% when a glp-1 receptor agonist is added to novomix 30, to minimise the risk of hypoglycaemia. for patients with an hba1c higher than 8% a dose reduction should be considered. subsequently, dosage should be adjusted individually.

Australia - English - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - insulin lispro, quantity: 200 iu/ml - injection, solution - excipient ingredients: glycerol; zinc oxide; trometamol; water for injections; hydrochloric acid; sodium hydroxide; metacresol - for the treatment of patients with type 1 (iddm) and type 2 (niddm) diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis.

Canada - English - Health Canada

eli lilly canada inc - insulin; insulin isophane (nph) - suspension - 30unit; 70unit - insulin 30unit; insulin isophane (nph) 70unit - insulins

Canada - English - Health Canada

wockhardt uk limited - insulin isophane injection pork - suspension - 100unit - insulin isophane injection pork 100unit - insulins

Canada - English - Health Canada

wockhardt uk limited - insulin injection pork - solution - 100unit - insulin injection pork 100unit - insulins

Australia - English - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - insulin, quantity: 100 iu/ml - injection, suspension - excipient ingredients: dibasic sodium phosphate dihydrate; sodium hydroxide; zinc chloride; phenol; hydrochloric acid; glycerol; water for injections; protamine sulfate; metacresol - the treatment of insulin-requiring diabetes.

Australia - English - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - insulin, quantity: 100 iu/ml - injection, suspension - excipient ingredients: dibasic sodium phosphate dihydrate; phenol; hydrochloric acid; water for injections; metacresol; zinc chloride; protamine sulfate; sodium hydroxide; glycerol - the treatment of insulin-requiring diabetes.

Australia - English - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - insulin, quantity: 100 iu/ml - injection, suspension - excipient ingredients: hydrochloric acid; zinc chloride; protamine sulfate; sodium hydroxide; metacresol; dibasic sodium phosphate dihydrate; water for injections; glycerol; phenol - the treatment of insulin-requiring diabetes.

Australia - English - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - insulin, quantity: 50 iu/ml - injection, suspension - excipient ingredients: dibasic sodium phosphate dihydrate; glycerol; metacresol; hydrochloric acid; zinc chloride; sodium hydroxide; phenol; water for injections; protamine sulfate - the treatment of insulin-requiring diabetes.

Australia - English - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - insulin, quantity: 70 iu/ml; insulin, quantity: 30 iu/ml - injection, suspension - excipient ingredients: protamine sulfate; dibasic sodium phosphate dihydrate; hydrochloric acid; glycerol; zinc chloride; sodium hydroxide; metacresol; water for injections; phenol - the treatment of insulin-requiring diabetes.